A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Sunitinib (Primary) ; Varlilumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celldex Therapeutics Inc
- 18 Apr 2017 Planned End Date changed from 1 Mar 2019 to 1 Sep 2017.
- 18 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
- 15 Mar 2017 Status changed from active, no longer recruiting to discontinued.